Respiratory syncytial virus infectious disease
MONDO:0001577Infection with the respiratory syncytial virus, an RNA virus of the genus Pneumovirus, in the family Paramyxoviridae, which is characterized by the formation of syncytia in tissue culture. It causes minor respiratory infection with rhinitis and cough in adults, but is capable of causing severe bronchitis and bronchopneumonia in young children.
Also known as: Human respiratory syncytial virus infection, respiratory syncytial virus infection, infections, Human respiratory syncytial virus
226 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New RSV vaccine for infants shows promise in major trial
⭐️ VACCINE ⭐️ TerminatedThis study tested an experimental RSV vaccine given to healthy infants at 6 and 12 months old alongside their regular vaccines. The goal was to see if the RSV vaccine still worked well when given at the same time. About 2,200 babies took part, but the study was stopped early.
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
Could a Lower-Dose RSV vaccine protect babies just as well?
⭐️ VACCINE ⭐️ TerminatedThis study tested a nasal spray RSV vaccine in nearly 1,000 healthy infants and toddlers aged 6 to 22 months. The goal was to see if a lower dose works as well as the standard dose and to check safety across different doses. The trial was ended early, so final results are not ava…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
RSV nasal vaccine trial for kids halted – what we know
⭐️ VACCINE ⭐️ TerminatedThis phase 3 study tested an intranasal RSV vaccine in about 6,300 healthy children aged 6 to 22 months. The goal was to see if two doses of the nasal spray could prevent lower respiratory tract infections caused by RSV. The trial was terminated early, so final results are not av…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
Could a simple pill tame RSV? new trial tests obeldesivir
Disease control TerminatedThis phase 2 study tests whether an oral antiviral pill called obeldesivir can safely shorten RSV symptoms in adults who are not hospitalized but are at higher risk for severe disease (e.g., those aged 60+ or with chronic lung conditions). Participants take the pill or a placebo,…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New oral pill aims to fight RSV in adults
Disease control TerminatedThis study tests an oral drug called AK0529 (Ziresovir) in adults aged 18 to 75 with respiratory syncytial virus (RSV) infection. Participants receive either the drug or a placebo, and researchers measure how well symptoms improve and track any side effects. The goal is to see if…
Phase: PHASE2 • Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New RSV drug tested in kids – but trial halted early
Disease control TerminatedThis study tested the safety and dosing of sisunatovir, an experimental antiviral drug, in infants and children up to 5 years old with RSV lower respiratory tract infection. Ten participants received either the drug or a placebo. The goal was to find the right dose for future stu…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
RSV pill study halted early: what we know
Disease control TerminatedThis study tested an oral drug called sisunatovir for treating RSV in adults who were not hospitalized but had a high risk of severe illness. Participants took either the drug or a placebo for 5 days. The study was terminated early, so results are limited.
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
RSV drug trial for kids under 5 halted early – only 4 children enrolled
Symptom relief TerminatedThis study tested an oral antiviral drug called obeldesivir in children from birth to under 5 years old who had RSV infection. The goal was to see if the drug is safe and helps reduce symptoms faster. However, the trial was stopped early and only enrolled 4 participants, so the r…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Sticker shock: simple reminder may cut unnecessary IV antibiotic use
Knowledge-focused TerminatedThis study tested whether placing a reminder sticker on the charts of adult hospital patients receiving IV fluoroquinolone antibiotics would encourage doctors to switch them to oral pills sooner. The trial involved 168 patients at a single hospital in Thailand. Unfortunately, the…
Phase: NA • Sponsor: Mahidol University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC